Physician profile
John David Cranor
NPI 1962516328
$1,166.31
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $291 · 2021: $376 · 2022: $170.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $533.85 | 2019-2022 | |
| Esperion Therapeutics, INC. | $138.74 | 2020 | |
| Lilly USA, LLC | $103.46 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $96.88 | 2020-2021 | |
| Alfasigma USA, INC. | $54.99 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $35.06 | 2019 | |
| Pfizer INC. | $34.00 | 2021 | |
| Genentech USA, INC. | $26.20 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.94 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.15 | 2019 | |
| Shire North American Group INC | $13.56 | 2019 | |
| Daiichi Sankyo INC. | $13.45 | 2020 | |
| Abbvie INC. | $13.12 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.08 | 2021 | |
| Hikma Pharmaceuticals USA | $12.69 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Merck Sharp & Dohme LLC | $11.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cranor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.